GSK Plans To Divest Old Drugs, Except In Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline aims to have a close and careful review of its older drugs in emerging markets before selling them, taking a piecemeal approach to a complex geographic sales puzzle, Scrip Intelligence reports.